CancerDrs Find care

Colorectal Cancer clinical trials in Colorado

37 actively recruiting colorectal cancer trials at 19 sites across Colorado.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Colorado:
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • Saint Francis Cancer Center — Colorado Springs, Colorado
  • CommonSpirit Cancer Center Mercy — Durango, Colorado
  • Mercy Medical Center — Durango, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused telisotuzumab adizutecan to …

Sponsor: AbbVie
NCT ID: NCT06614192
Sites in Colorado:
  • Lutheran Medical Center- Cancer Centers of Colorado /ID# 268175 — Golden, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Colorado:
  • Local Institution - 1003 — Aurora, Colorado
  • Local Institution - 2103 — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Colorado:
  • Rocky Mountain Cancer Center — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Colorado:
  • Children's Hospital Colorado — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Colorado:
  • HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…

Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uv…

Sponsor: IDEAYA Biosciences
NCT ID: NCT03947385
Sites in Colorado:
  • SCRI - Denver — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.

Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT06948448
Sites in Colorado:
  • Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

SMP-3124LP in Adults With Advanced Solid Tumors

An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT06526819
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthOne — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy. This study will evaluate whether additional "focal" radiation…

Sponsor: University of Colorado, Denver
NCT ID: NCT07292298
Sites in Colorado:
  • University of Colorado Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Colorado:
  • Exelixis Clinical Site #87 — Littleton, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Colorado:
  • Rocky Mountain Cancer Centers — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …

Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Colorado:
  • Clinical and Translational Research Center (CTRC) — Aurora, Colorado
  • UCHealth Sue Anschutz-Rodgers Eye Center — Aurora, Colorado
  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado
  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker…

Sponsor: Hoffmann-La Roche
NCT ID: NCT04929223
Sites in Colorado:
  • University of Colorado Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Colorado:
  • University of Colorado Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have…

Sponsor: Pfizer
NCT ID: NCT06447662
Sites in Colorado:
  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado
  • University of Colorado Hospital - Anschutz Outpatient Pavilion — Aurora, Colorado
  • University of Colorado Hospital- Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
  • University of Colorado Hospital — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…

Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthOne — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Colorado:
  • University of Colorado - Aurora Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory), that has co…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06102902
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
View on ClinicalTrials.gov →

Showing 25 of 37 trials with sites in Colorado. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20